Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study

Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study

Objective: To estimate population health outcomes with delayed second dose versus standard schedule of SARS-CoV-2 mRNA vaccination. Design: Simulation agent based modeling study. Setting: Simulated population based on real world US county. Participants: The simulation included 100 000 agents, wit...

Full description

Bibliographic Details
Main Authors:	Romero-Brufau, Santiago, Chopra, Ayush, Ryu, Alex J, Gel, Esma, Raskar, Ramesh, Kremers, Walter, Anderson, Karen S, Subramanian, Jayakumar, Krishnamurthy, Balaji, Singh, Abhishek, Pasupathy, Kalyan, Dong, Yue, O’Horo, John C, Wilson, Walter R, Mitchell, Oscar, Kingsley, Thomas C
Other Authors:	Massachusetts Institute of Technology. Media Laboratory
Format:	Article
Published:	BMJ Publishing Group 2021
Online Access:	https://hdl.handle.net/1721.1/130653

Similar Items

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
by: Ilias Mavrovouniotis, et al.
Published: (2023-02-01)

Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors
by: Madison Ballman, BA, et al.
Published: (2021-10-01)

Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
by: Chapin S. Korosec, et al.
Published: (2022-12-01)

Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
by: Ilir Alimehmeti
Published: (2021-01-01)

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
by: Kaplonek, Paulina, et al.
Published: (2023)

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
by: Nazmul Islam, et al.
Published: (2022-05-01)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
by: Helly Hammer, et al.
Published: (2022-06-01)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
by: Michal Canetti, et al.
Published: (2022-12-01)

Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
by: Cécile Janssen, et al.
Published: (2022-06-01)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
by: Kazuki Takada, MD, PhD, et al.
Published: (2021-11-01)

Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
by: José Jesús Broseta, et al.
Published: (2022-03-01)

Comparativa de la respuesta inmunitaria en diálisis tras dos y tres dosis de ARNm-1273 o BNT162b2
by: José J. Ribés-Cruz, et al.
Published: (2023-01-01)

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies
by: Shuailei Chang, et al.
Published: (2022-03-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
by: Michal Canetti, et al.
Published: (2023-03-01)

Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients
by: Matthias Becker, et al.
Published: (2022-10-01)

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
by: Anna Kaznadzey, et al.
Published: (2022-04-01)

Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP
by: Hulme, WJ, et al.
Published: (2023)

The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data
by: Soonok Sa, et al.
Published: (2022-02-01)

Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series
by: Elif Karatas, MD, et al.
Published: (2023-02-01)

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273
by: Brian Grunau, et al.
Published: (2022-04-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort
by: Oliver Bürzle, et al.
Published: (2023-04-01)

Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines
by: Manan Pareek, et al.
Published: (2023-11-01)

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
by: Dominique J. Barbeau, et al.
Published: (2022-07-01)

Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework
by: Xuan Wang, et al.
Published: (2023-09-01)

The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study
by: Sanaa M. Kamal, et al.
Published: (2023-01-01)

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
by: Thomas E. Hickey, et al.
Published: (2023-08-01)

Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers
by: Wendy M. Brunner, et al.
Published: (2022-10-01)

Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS
by: Ming-Ming Yan, et al.
Published: (2022-11-01)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
by: Geon Young Ko, et al.
Published: (2023-10-01)

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
by: Farah M. Shurrab, et al.
Published: (2022-01-01)

Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain
by: Leire Fernández-Ciriza, et al.
Published: (2022-10-01)

Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2
by: Richard Vollenberg, et al.
Published: (2022-01-01)

Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
by: Nigam H. Padhiar, et al.
Published: (2022-05-01)

mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals
by: Roberto Lozano-Rodríguez, et al.
Published: (2023-04-01)

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
by: Giulia Vivaldi, et al.
Published: (2022-11-01)

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
by: Kevin Yau, et al.
Published: (2023-09-01)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
by: Passakorn Wanchaijiraboon, et al.
Published: (2023-02-01)

Demonstration of Antibodies Against SARS-CoV-2, Neutralizing or Binding, in Seroconversion Panels After mRNA-1273, BNT-162b2, and Ad26.COV2.S Vaccine Administration
by: Francisco Belda BSc, MS, PhD, et al.
Published: (2023-09-01)